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We addressed the questions of how cerebral glucose transport and
phosphorylation change under acute hypoglycemia and what the
underlying mechanisms of adaptation are. Methods: Quantitative
18F-FDG PET combined with the acquisition of real-time arterial in-
put function was performed on mice. Hypoglycemia was induced
and maintained by insulin infusion. PET data were analyzed with the
2-tissue-compartment model for 18F-FDG, and the results were eval-
uated with Michaelis–Menten saturation kinetics. Results: Glucose
clearance from plasma to brain (K1,glc) and the phosphorylation rate
constant increased with decreasing plasma glucose (Gp), in partic-
ular at a Gp of less than 2.5 mmol/L. Estimated cerebral glucose
extraction ratios taking into account an increased cerebral blood
flow (CBF) at a Gp of less than 2 mmol/L were between 0.14 and 0.79.
CBF-normalized K1,glc values were in agreement with saturation ki-
netics. Phosphorylation rate constants indicated intracellular glu-
cose depletion at a Gp of less than 2–3 mmol/L. When brain regions
were compared, glucose transport under hypoglycemia was lowest
in the hypothalamus. Conclusion: Alterations in glucose transport
and phosphorylation, as well as intracellular glucose depletion, un-
der acute hypoglycemia can be modeled by saturation kinetics tak-
ing into account an increase in CBF. Distinct transport kinetics in the
hypothalamus may be involved in its glucose-sensing function.
Key Words: brain glucose metabolism; hypoglycemia; Michaelis–
Menten kinetics; positron-emission tomography
J Nucl Med 2013; 54:2153–2160
DOI: 10.2967/jnumed.113.122812
Blood-borne glucose is the major source of energy for neuro-
nal activity. The rate-determining processes involved in cerebral
glucose consumption are glucose transport by hexose transporters
(GLUTs) and glucose phosphorylation by hexokinase I (1). Both
processes underlie Michaelis–Menten saturation kinetics and can
adapt to some extent to chronic hypo- or hyperglycemia. Studies
in rats have revealed several possible processes by which the brain
adapts to glucose deprivation during acute, recurrent, or chronic
hypoglycemia. Glucose permeability of the blood–brain barrier
(BBB) is increased in models of chronic hypoglycemia. Amplified
synthesis and translocation of GLUT1 to the plasma membrane of
microvascular endothelial cells have been demonstrated (2–4). In
addition, upregulation of neuronal GLUT3 expression is likely to be
involved in the brain’s adaptation to chronic hypoglycemia (4,5).
Less is known about adaptations under acute hypoglycemia.
Cerebral blood flow (CBF) and, therefore, glucose delivery are
increased at a plasma glucose level (Gp) of less than 2 mmol/L (6).
Increased glucose permeability of the BBB and in particular trans-
location of GLUT1 to the cell surface have been suggested as causal
mechanisms for elevated transport (6–8). Awareness of acute hy-
poglycemia is a vital response to low Gp. Hypoglycemia unawareness
is a life-threatening problem in patients with type 1 insulin-treated
diabetes of long duration and repeated episodes of hypoglycemia.
There is ample evidence that the hypothalamus has a glucose-
sensing function. Although GLUT1 is the major glucose trans-
porter at the BBB in general, some regions in the hypothalamus
contain high levels of GLUT2 (9). Two major features of
GLUT2 may be involved in glucose sensing. GLUT2 has
a higher Michaelis–Menten constant KT than GLUT1 (10), and
a glucose-sensing receptor function was described for an intracellular
sequence of GLUT2 (9). In addition, the rate of glucose phosphory-
lation was found to be altered specifically in the hypothalamus
after a history of hypoglycemia (11).
Kinetic modeling of brain uptake of the glucose analog 18F-FDG
allows investigation of changes in cerebral glucose homeostasis in
vivo. So far, 18F-FDG PET studies have focused on the cerebral
metabolic rate of glucose (CMRglc) in rats. 18F-FDG PET on mice
rather than rats has a greater potential to address specific questions
related to human metabolic and neurologic diseases, as the mouse
is the preferred species for transgenic disease models. CMRglc can
be estimated from PET data without the requirement of a highly
time-resolved input function (12). However, CMRglc provides no
information on the individual contributions of transport and phos-
phorylation to glucose consumption. In addition, for a correct de-
termination of CMRglc, the so-called lumped constant (LC) is in-
dispensable, correcting for differences between 18F-FDG and glucose
with respect to transport and phosphorylation kinetics, respec-
tively (13,14). LC is often used as a Gp-independent parameter
although the relative contributions of transport and phosphoryla-
tion may vary, depending on Gp.
The key limiting factor for determining both transport and phos-
phorylation kinetics in mice is the small blood volume and the
resulting difficulty in measuring an adequate arterial input function.
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To overcome this issue, we adapted an earlier protocol for rats (15)
to measurements in mice. This protocol is based on an arteriove-
nous shunt and a coincidence counter to record input functions
with a high temporal resolution (16). With this, the rate constants
of the single processes, that is, 18F-FDG transport and phosphor-
ylation, are accessible.
Extending our data from normoglycemic mice (16) to data from
mice undergoing insulin-induced acute hypoglycemia, we addressed
the question of how acute hypoglycemia affects the kinetics of
regional glucose transport and phosphorylation in the mouse brain.
We evaluated whether the observed alterations are the consequen-
ces of saturation kinetics and increased CBF alone or whether
additional physiologic adaptations such as alterations in barrier
permeability need to be considered to model the data.
MATERIALS AND METHODS
Animal Preparation
Animal experiments were in accordance with the Swiss Animal Pro-
tection Law and were approved by the Veterinary Office of the Canton
Zurich. To exclude strain-specific effects, we included 2 strains. Male
CD1 (n5 10; weight, 34.26 2.5 g [mean6 SD]) and C57BL/6 (n5 5,
27.1 6 2.8 g) mice (Charles River) were housed under standard con-
ditions. Data from non–insulin-treated animals (n 5 14) were from
recent experiments (16). Animals were prepared as described previ-
ously for the acquisition of PET/CT and input function (16). Briefly,
catheters were inserted into the femoral artery and vein and were
connected to form a closed shunt loop, which was guided through a
coincidence counter (twilite; Swisstrace) and a peristaltic pump at a
constant flow of 120 mL/min. Two 3-way valves were used for insulin
and 18F-FDG infusion.
Insulin Infusion and Blood Sampling
Insulin (Actrapid, 1 IU/mL; Novo Nordisk) infusion rates were
dependent on the animal weight and the initial and target Gp concen-
trations. For a mouse weighing 30 g, insulin infusion started with
9 mL/min for 1 min and then was decreased stepwise over 4 min to
a constant rate of 3 mL/min. Whole-blood glucose was measured in
samples of 5 mL with a blood glucose meter (Ascensia; Bayer Health-
Care LLC) up to 4 times before the start of the PET scan. Blood
glucose levels reached a steady state 10–15 min after infusion began.
A larger arterial blood sample was drawn immediately after the PET
scan. Plasma was separated by centrifugation, and Gp was measured
with a glucose oxidase/reflectance system (Vitros DT60 II; Ortho
Clinical Diagnostics).
Imaging
PET scanning and 18F-FDG infusion were started simultaneously
when Gp had reached a plateau of less than 2.5 mmol/L. The isoflur-
ane dose was adjusted to maintain the respiratory rate at between 75
and 100 bpm, and body temperature was kept between 36.5C and
37.3C. PET acquisition was performed as described previously with
a VISTA eXplore PET/CT scanner (GE Healthcare, 0.9-mm resolution
in full width at half maximum in the center of the field of view) (16).
PET data were reconstructed to a nominal voxel volume of 0.116
mm3. Whole-blood radioactivity was recorded in real time with the
coincidence counter and translated to plasma 18F-FDG concentration
(16). Injected 18F-FDG doses were 10–15 MBq (40–60 pmol) in 200
mL, resulting in plasma 18F-FDG concentrations of less than 10 nM.
PET/CT images were coregistered with the PMOD software (PMOD
Technologies Inc.) to a mouse brain template provided by PMOD. Tem-
plate volumes of interest were used to generate time–activity curves
for the following structures: cerebrum (362 mm2), cortex (149 mm2),
striatum (25.8 mm2), hippocampus (25.0 mm2), thalamus (28.2 mm2),
hypothalamus (11.6 mm2), and cerebellum (57.2 mm3) (Supplemental
Fig. 1; supplemental materials are available at http://jnm.snmjournals.org).
Kinetic Modeling
Time–activity curves were analyzed by 2-tissue-compartment 18F-
FDG kinetic modeling with PMOD as described previously (16) to
determine the clearance K1,FDG (mL/min per cm3 tissue) for 18F-FDG
transport from plasma to brain and the rate constants (1/min) k2,FDG
for reverse transport, k3,FDG for 18F-FDG phosphorylation, and k4,FDG
for dephosphorylation (17). Image data were corrected for blood ra-
dioactivity with a fractional cerebral blood volume of 5.5% (18). The
transport rate of glucose from plasma to tissue (Tglc, mmol/min/100 g)
was calculated according to Equation 1,
Tglc 5 K1;FDG ·
1
L1
· Gp ·
1
r
· 100 5 K1;glc · Gp ·
1
r
· 100;
Eq. 1
with Gp being in mmol/L and r being brain tissue density of 1.04 g/cm3
(19). L1 is the ratio between K1,FDG and K1 of glucose (K1,FDG/K1,glc 5
1.48). L1 corrects for differences in 18F-FDG and glucose transport
kinetics and was determined in nonsedated humans at a Gp of 3–16
mmol/L and was about 10% lower than estimated for pentobarbital-
anesthetized rats (20) (supplemental data).
Influence of CBF on K1,glc and Tglc
The extraction ratio of glucose from plasma to brain tissue (Eglc)
was estimated with Equation 2. The permeability–surface area product
(PSglc), that is, K1,glc values at infinite CBF, was extrapolated with
Equation 3. Hypothetical K1,glc at a given CBF was estimated from
PSglc with Equation 4 (21):
Eglc 5
K1;glc
CPF
; Eq. 2
PSglc 52CPF · ln

1 2 Eglc

; Eq. 3
K1;glc 5 CPF ·

1 2 e2
PSglc
CPF

; Eq. 4
with CPF being cerebral plasma flow, that is, the product of [1 2
hematocrit 5 0.56] (22) and CBF in mL/min/cm3. At a Gp of more
than 2 mmol/L, a CBF of 1.30 mL/min/cm3 (averaged from (23),
excluding corpus callosum) was used except for the hypothalamus,
for which a CBF of 0.86 mL/min/cm3 was used (24). An increase in
CBF by 57% (supplemental data: 0%–100%) was assumed at a Gp of
less than 2 mmol/L (6,25).
Michaelis–Menten Saturation Kinetics
To estimate Michaelis–Menten parameters, average Gp along the
capillary (G9p) was calculated from the arterial Gp with Equation 5.
The correction was not applied to Gp in Equation 1, because a similar
reduction in the concentration of 18F-FDG (input function) and Gp
along the capillary was assumed. K1,FDG is thus underestimated by
a factor similar to G9p/Gp.
G
0
p 5 Gp

1 2 Eglc

1 2 e21

: Eq. 5
Michaelis–Menten functions as shown in Equations 6 and 7 (and
the supplemental data) were fit to K1,glc and Tglc, respectively, by least-
squares regression analysis (SigmaPlot, version 12.5; Systat Software
Inc.). K1,glc values at a Gp of less than 2 mmol/L were normalized to
physiologic CBF with Equations 2–4 to exclude the effect of increased
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CBF. Estimated parameters were the maximal capacity (Tmax), G9p at
half Tmax (KT), and Tmax/KT (K1,glc1st order) for glucose transport.
Multiplication of Equation 6 by Gp reveals Equation 7.
K1;glc 5
Tmax
KT;glc1G
0
p
5
K1st order1;glc
11
G
0
p
KT;glc
Eq. 6
Tglc 5
Tmax · G
0
p
KT;glc1G
0
p
·
1
r
· 100 Eq. 7
Equation 6 was used correspondingly to analyze k3,glc (L3 5
k3,FDG/k3,glc 5 0.38 (20)). Tmax was replaced by Vmax · Gp/Gi, the
maximal phosphorylation velocity, where Gp/Gi is the correction
factor for the ratio between Gp and intracellular glucose concentra-
tion (Gi). KT was replaced by KM, that is, G9p at half maximal
Vmax · Gp/Gi. Fitting for (Vmax · Gp/Gi)/KM revealed k3,glc1st order.
The 18F-FDG uptake rate constant (KFDG), the relative volume of
distribution (VD), and CMRglc were calculated according to Equa-
tions 8–10 with LCs as described below.
KFDG 5
K1;FDG · k3;FDG
k2;FDG1 k3;FDG
Eq. 8
VD 5
K1;FDG
k2;FDG
1
K1;FDG · k3;FDG
k2;FDG · k4;FDG
Eq. 9
CMRglc 5
KFDG · Gp
LC
Eq. 10
LC
The CMRglc of the cerebrum was estimated with 3 LCs: LC1, an
invariable LC of 0.6 (26,27); LC2, a Gp-adjusted LC derived from the
values reported for awake rats by Suda et al. (13) (for this purpose, we
multiplied the LC values in rats by a factor of 1.35, to reach an LC of
0.6 on average in normoglycemic animals); and LC3, the LC derived
from experimental parameters as proposed by Backes et al. and shown
in Equation 11 (28), assuming L1 5 L2 5 1.48 and L3 5 0.38 (20).
LC3 5
K1;FDG · k3;FDG
k2;FDG · k3;FDG
L1 · K1;FDG · L3 · k3;FDG
L2 · k2;FDG 1L3 · k3;FDG
5 L1 ·

L3
L2
1
	
1 2
L3
L2


·
KFDG
K1;FDG

Eq. 11
Estimation of Intracellular Glucose Concentration
The intracellular glucose concentration Gi was iteratively estimated
from Gp according to Equation 12.
Gi 5 Gp ·
K1;glc
k3;glc1 k2;glc
5 Gp ·
Tmax
KT;glc 1Gp
Vmax · Gp=Gi
Gp=Gi ðat Gp5 5 mmol=LÞ
KM;glc 1Gi
1 TmaxKT;glc 1Gi
Eq. 12
Gp/Gi at a Gp of 5 mmol/L, where hexokinase I is saturated but not
GLUT1, was determined by iteration; KM was 0.04 mmol/L (29). All
other parameters were fit as described above.
Statistics
The influence of brain region on single rate constants, KFDG, and
CMRglc was assessed with repeated-measures ANOVAwith brain region
as the within-subject factor (cortex, striatum, hippocampus, thalamus,
cerebellum, and hypothalamus, i.e., df 5 5). Significant F values are
reported. For the purpose of post hoc testing with 2-tailed, homosce-
dastic t tests, data from regions with a significant within-subject effect
were separated into a hypoglycemic group (Gp , 2.5 mmol/L, corre-
sponding to G9p , 2 mmol/L) and a normoglycemic group (Gp . 2.5
mmol/L). All data are shown with associated SD unless otherwise
stated. The supplemental data report R2.
RESULTS
The insulin-clamp protocol resulted in a Gp of 1.96 0.3 mmol/L
(n 5 14, plus 1 outlier with 3.8 mmol/L because the initial infu-
sion rate was accidentally reduced). 18F-FDG plasma clearance
was faster in hypoglycemic than normoglycemic animals (Fig. 1).
Influence of CBF on Cerebral Glucose Transport
As shown in Figure 2A, K1,glc (K1,FDG/L1) was highest at a low
Gp and decreased with increasing Gp. Tglc followed a typical sat-
uration function (Supplemental Fig. 2). Because CBF increases
abruptly at a Gp of less than 2 mmol/L in rats (6,25), we first in-
vestigated to what extent a similar increase in CBF would affect
K1,glc. We assumed a 57% increase in CBF at a Gp of less than
2 mmol/L from 1.30 to 2.04 mL/min/cm3 (6,23,24) and estimated
the corresponding hypothetic K1,glc at 1.30 mL/min/cm3 with
Equations 2–4. Figure 2A and Supplemental Figure 3 show the
uncorrected and CBF-normalized K1,glc values. At a Gp of less
than 2 mmol/L (CBF, 2.04 mL/min/cm3), PS ranged from 0.22
to 0.80 mL/min/cm3 (0.40 6 0.19); at a Gp of 2–3 mmol/L (CBF,
1.30 mL/min/cm3), from 0.24 to 0.41 (0.336 0.06); and at a Gp of
more than 3 mmol/L, from 0.11 to 0.35 (0.22 6 0.07). Eglc was
between 0.14 (highest Gp) and 0.79 (lowest Gp). The estimated
average increase in K1,glc, Tglc, and KFDG due to the assumed 57%
increase in CBF was 9% (6%–19%). Doubling the CBF would
result in an estimated average increase of 13% (7%–25%). Simu-
lations for K1,glc, Eglc, and PSglc with CBF increases of between 0%
and 100% and 2 different L1 values are shown in Supplemental
FIGURE 1. Brain time–activity curves and arterial input functions in
representative normoglycemic mouse (norm, Gp 6.7 mmol/L) and hypo-
glycemic mouse (hypo, Gp 2.1 mmol/L).
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Figures 4–6. Supplemental Figure 4 also shows G9p in relation to Gp.
K1,glc was additionally calculated from PSFDG/L1 to evaluate possible
artifacts due to CPF-limited transport when K1,FDG/K1,glc approaches
1 and K1,FDG/L1 underestimates K1,glc (Supplemental Fig. 7).
Influence of Glucose Concentration on Transport
and Phosphorylation
The K1,glc and Tglc of the cerebrum were further analyzed with
Michaelis–Menten saturation kinetics. To normalize for changes in
CBF, K1,glc and Tglc values at a Gp of less than 2 mmol/L were esti-
mated for physiologic CBF as described above. The fit parameters
obtained with Equations 6 and 7 are shown in Figure 2A and Sup-
plemental Figures 4, 5, and 7 for CBF increases of between 0% and
100% and for L1 values of 1.48 (humans) and 1.66 (pentobarbital-
anesthetized rats). Depending on L1 and the assumed CBF increase
at a Gp of less than 2 mmol/L, Kt varied between 6.76 2.5 mmol/L
(L1 5 1.48, no CBF increase) and 9.3 6 2.9 mmol/L (L1 5 1.48,
100% CBF increase) and Tmax between 2156 62 mmol/min/100 g
(L 5 1.66, no CBF increase) and 289 6 71 mmol/min/100 g (L 5
1.48, 100% CBF increase).
The efflux rate constant k2 scattered between 0.11 and 0.76/min
and did not correlate with Gp (Supplemental Fig. 8). To visualize
the influence of Gp on glucose partitioning at the BBB, the partition
coefficient K1,FDG/k2,FDG was plotted ver-
sus G9p (Fig. 2B). Net glucose partitioning
from plasma to brain was higher in hypo-
glycemia than normoglycemia.
Plotting k3,glc over G9p showed a sharp
increase in k3,glc at a G9p of less than 2.0
mmol/L (Gp , 2.5 mmol/L; Fig. 2C). Fit
parameters of the analysis with Equation 6
are shown in Figure 2C. The intracellular
balance between 18F-FDG phosphorylation
(k3,FDG · Gi) and efflux (k2,FDG · Gi) is
shown in Figure 2D (k3,FDG/k2,FDG). The
ratio k3,FDG/k2,FDG was not influenced by
a Gp of above 2.5 mmol/L but was signif-
icantly increased below 2.5 mmol/L (G9p ,
2 mmol/L) (k3/k2 5 0.24 6 0.10, n 5 14,
at euglycemia, vs. 0.87 6 0.60, n 5 14, at
Gp , 2.5 mmol/L; P , 0.001). Dephos-
phorylation of FDG-6-phosphate as de-
scribed by k4,FDG was significantly different
from zero in all animals, with high scatter-
ing and no obvious dependence on Gp (Sup-
plemental Fig. 9). KFDG and VD were derived
from the single rate constants and showed
respective patterns (Fig. 3 and Supplemen-
tal Fig. 10). Both increased when Gp was
reduced.
Figure 4A shows the LCs as described in
the “Materials and Methods” section. When
estimated with a fixed LC of 0.6, CMRglc
was independent of Gp (60 6 5 vs. 51 6 6
mmol/min/100 g in animals with a Gp
greater and less than 2.5 mmol/L, respec-
tively) despite the significant increases in
Tglc (Supplemental Fig. 2) and k3,FDG · Gp
(not shown) with increasing Gp. However,
when LC2 or LC3 was applied, the average
CMRglc in animals with a Gp of more than
2.5 mmol/L was higher in all brain structures examined than the
average CMRglc in animals with a Gp of less than 2.5 mmol/L (all
P , 0.003, Table 1; Figs. 4B and 4C).
Brain-Region–Specific Response to Hypoglycemia
Brain region had a significant influence on K1,FDG (F5 7.468, P,
0.0005), KFDG (F 5 14.346, P , 0.0005), and CMRglc (F 5 24.523,
P , 0.0005) but not on k2,FDG, k3,FDG, and k4,FDG (all P . 0.28).
CMRglc was estimated with LC1 in this analysis. The use of either
LC2 or LC3 yielded the same conclusion. Pairwise comparison showed
significantly lower KFDG and CMRglc in the hypothalamus and cortex
than in any other brain region included in the analysis. In addition,
K1,FDG was lower in the hypothalamus than in any other structure.
The differences in K1,FDG and KFDG between the hypothalamus and
other brain regions were dependent on Gp: although K1,FDG and
KFDG were not significantly different between brain regions at a Gp of
more than 2.5 mmol/L, they were less increased (by 15% and 19%)
under hypoglycemia in the hypothalamus than in other brain structures.
The findings in the cortex were similar (12% and 17% less increase
for K1,FDG and KFDG, respectively). These findings are summarized in
Table 2, and dot–box plots are shown in Supplemental Figure 11.
Differences in CMRglc between the regions were independent of
Gp, that is, there was no region · Gp interaction influencing CMRglc.
FIGURE 2. (A) Glucose clearance K1,glc from plasma to brain increases with decreasing Gp. K1,glc
at Gp of less than 2 mmol/L was normalized for CBF. (B) 18F-FDG partitioning at BBB (K1,FDG/k2,FDG)
with sharp increase below G9p 2 mmol/L (dashed line). (C) k3,glc sharply increased at G9p of less than
2 mmol/L. (D) Intracellular balance between 18F-FDG phosphorylation and efflux (k3,FDG/k2,FDG).
Open symbols 5 insulin-treated; closed symbols 5 untreated; squares 5 57BL/6 mice; circles 5
CD1 mice; crosses 5 not corrected for CBF increase (Supplemental Fig. 3); solid black line 5 fit
with Equation 6 (fit parameters in graph); dashed blue lines 5 95% confidence band; dashed red
lines 5 95% prediction band. R2 5 0.553 (A), 0.616 (C).
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K1,glc, Tglc, and k3,glc of the respective brain regions were fit to
G9p with Equations 6 and 7. Figure 5, Supplemental Figure 12, and
Supplemental Figure 13 show the respective data and fits for glu-
cose transport. As found for the cerebrum (Fig. 2A and Supple-
mental Fig. 2), transport in the cortex, striatum, hippocampus, and
thalamus followed typical saturation kinetics. However, plots from
the cerebellum and in particular the hypothalamus had a less pro-
nounced shape of saturation. When fit with both Equation 6 and
Equation 7, the hypothalamus had the highest Tmax and KT at the
lowest K1,glc1st order of all studied regions (Fig. 5, Supplemental
Fig. 12, and Supplemental Fig. 13). This case was also true when
K1,glc was calculated via PSglc/L1 (assuming a 57% CBF increase
at a Gp of less than 2 mmol/L) and when normalization was to 1.3
instead of 0.86 mL/min/cm3 CBF, indicating that CBF was not
responsible for these observations. The hypothalamus thus has the
highest glucose influx at a high Gp but the lowest influx under
hypoglycemia. Region-specific k3,glc as a function of G9p had similar
patterns for all investigated brain regions (Supplemental Fig. 14).
Estimation of Intracellular Glucose Concentrations
The estimated cerebral and hypothalamic Gi is shown in Figure
6 as a function of Gp. Although the estimated Gi was similar in
both brain regions at a Gp of 6.4 mmol/L (i.e., Gi 5 2.0 mmol/L),
it was lower in the hypothalamus than in the cerebrum at a lower
Gp but higher at a Gp of more than 6.4 mmol/L. The estimated
Vmax of phosphorylation (Eq. 12) was 67.4 and 61.0 mmol/min/
100 g for the cerebrum and hypothalamus, respectively. These
values are close to the CMRglc values reported in Table 1.
DISCUSSION
Applying our recently published technique for highly time-
resolved monitoring of the 18F-FDG input function in mice (16),
we investigated glucose transport and phosphorylation kinetics in
mouse brain under acute insulin-induced hypoglycemia. We were
able to assign the increase in K1,glc under hypoglycemia to 2
mechanisms. First, our simulations revealed that the expected in-
crease in CBF at a Gp of less than 2 mmol/L (6,25) caused an
increase in K1,glc, Tglc, and KFDG by 6%–19%. The elevation in
CBF as a response to hypoglycemia was thus effectively improv-
ing glucose delivery to the brain parenchyma. In fact, as shown by
Equations 2–4, the higher the K1,glc and therefore Eglc were, the
stronger was the effect of CBF elevation on glucose transport.
After correction for the effect of CBF elevation at a low Gp,
even when assuming doubling of CBF, cerebral K1,glc values were
still higher at low than high Gp, and Tglc followed a typical satu-
ration function when plotted against G9p. This finding was ex-
pected, as the apparent KT of GLUT1, the major GLUT isoform
at the BBB, lies within the studied range of Gp. The fitted KT and
Tmax were in the range of published values for rats (1,6,30,31).
Applying L1 determined with pentobarbital-anesthetized rats in-
stead of L1 determined with nonsedated humans reduced Tmax by
about 10% without affecting Kt. We analyzed our data with the
standard (irreversible) Michaelis–Menten model, not taking into
account product inhibition—that is, transport inhibition or revers-
ible transport at significant glucose levels on the trans side of the
transporter (6). This explains the relatively high (apparent) KT
values when compared with experiments under zero trans condi-
tions (6,31). Another simplification was that we assumed only a
single mechanism for glucose transport and did not consider ad-
ditional saturable or nonsaturable routes (32). Regarding k2, we
FIGURE 3. KFDG shows clear dependence on Gp.
FIGURE 4. (A) LC determined with different methods: constant value of 0.6 (LC1) (26,27); estimated from rat data (LC2) (13); and estimated from L1,
L2, and L3 (LC3) (28). (B) CMRglc estimated with constant LC 0.6. (C) CMRglc dependence on Gp if calculated with Gp-dependent LC (LC2, LC3).
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did not expect a marked influence of Gp, as intracellular glucose
levels were assumed to be below the apparent KT of GLUT1.
Translocation of GLUT1 to the plasma membrane at a low Gp
(8) would result in an increase in k2 under hypoglycemia. This
possibility was not supported by our data, although the high scat-
tering in k2 would not allow detection of minute changes.
Hexokinase type I is the major hexokinase isoform in the brain
(33). The enzyme is saturated under normoglycemia, because KM
(40 mmol/L) is far below Gi (.1 mmol/L at Gp . 5 mmol/L)
(29,34). G9p at the half maximal phosphorylation rate was 2.3
mmol/L. This value is close to the reported Gp of 2 mmol/L in
rats, at which intracellular glucose becomes depleted (6,34). It
appears plausible that in our experiments intracellular glucose
levels reached the KM of hexokinase I at a G9p of 2.3 mmol/L,
resulting in an increase in k3,glc. Our simulation of Gi in the
cerebrum revealed that Gi equals 149 mmol/L at a G9p of 2.3
mmol/L. Gi was 40 mmol/L at a G9p of 1.3 mmol/L. Taking into
account the several assumptions made for this analysis and the
uncertainty of the fits at a low G9p, our results support our hypoth-
esis that the CBF increase and saturation kinetics alone can de-
scribe the physiologic responses to hypoglycemia in the mouse
brain, including intracellular depletion of glucose at a Gp of less
than 2 mmol/L.
One of our key findings is that both brain glucose transport and
phosphorylation rate constants determined with 18F-FDG PET de-
pend on Gp. This finding is in agreement with predictions from
theoretic analysis of the glia-vascular unit (1) and is supported by
MR spectroscopy data (31) but is in contrast to other PET studies
(27,35). A main reason for the discrepancies from previous PET
studies lies in the choice of the LC (13,14), in particular under
hypoglycemia. The influence of Gp was different on K1,FDG and
k3,FDG. As CMRglc depends on both parameters, LC is not a con-
stant but is dependent on Gp. Determining K1,FDG-k3,FDG helps to
avoid misinterpretations of 18F-FDG PET results by comparing
CMRglc values calculated with inaccurate LC values. LC3 (28)
allows Gp-dependent LC values, provided that species-specific
L1 to L3 is available. However, L1 should be defined as PSFDG/PSglc
to take into account the influence of CBF on K1,FDG/K1,glc, as this
ratio approaches 1 when CBF becomes rate-limiting. Alternatively,
and to validate LC3, experimentally determined LC values are re-
quired for mice over a broad Gp range, as done thus far in awake rats
(LC2) (13).
The ratio Tmax/CMRglc was constant under euglycemia in var-
ious nuclear magnetic resonance experiments. In rats anesthetized
with a-chloralose and enflurane, the ratio was 4.5–4.7 and 5.8,
respectively, estimated with the irreversible Michaelis–Menten
model (6,31). Tmax/CMRglc in mouse cerebrum in our study was
4.2 (LC2) and 4.1 (LC3), respectively, which is in the range of
published values for rats.
We found a peculiar pattern for glucose transport in the hypo-
thalamus. Both K1,glc- and Tglc-versus-G9p plots indicated a trans-
port mechanism with either high KT or absence of saturability
within the studied Gp range. At high but not low Gp, this finding
is in line with reports of a less restrictive BBB for glucose in this
brain region (34). Our high KT would be in agreement with the
reported presence of GLUT2 in the hypothalamus (36). The KT of
GLUT2 is around 17 mmol/L (37). However, the contribution of
GLUT2 to overall glucose transport in the hypothalamus is not
TABLE 2
Post Hoc Tests of Repeated-Measures Variance Analysis
HYP minus average CTX minus average
Gp K1,FDG KFDG K1,FDG KFDG
.2.5 mmol/L 20.017 6 0.046 20.007 6 0.008 20.007 6 0.017 20.009 6 0.008
,2.5 mmol/L 20.063 6 0.060* 20.035 6 0.015† 20.047 6 0.067* 20.028 6 0.015†
*P , 0.05.
†P , 0.0002.
Data are mL/min/cm3. Interaction of region · Gp was further explored with post hoc t tests. Compared with average of other brain
structures, hypoglycemia led to significantly smaller increase in K1,FDG and KFDG in hypothalamus (HYP) and cortex (CTX).
TABLE 1
CMRglc (mmol/min/100 g) Grouped by Gp, Estimated with Different LC
LC CTX STR HIP THA HYP CB CER
LC1 5 0.6 (26)
Gp . 2.5 mmol/L 56 6 29 62 6 25 65 6 27 66 6 29 55 6 19 71 6 28 66 6 27
Gp , 2.5 mmol/L 48 6 16 56 6 20 54 6 17 55 6 22 43 6 16 55 6 16 55 6 21
LC2 (13)
Gp . 2.5 mmol/L 56 6 34 62 6 30 65 6 32 65 6 35 54 6 23 71 6 33 66 6 32
Gp , 2.5 mmol/L 20 6 7* 23 6 9* 23 6 9* 23 6 9* 18 6 7* 23 6 9* 26 6 17*
LC3 (28)
Gp . 2.5 mmol/L 58 6 28 61 6 24 63 6 24 66 6 29 57 6 23 70 6 30 67 6 23
Gp , 2.5 mmol/L 33 6 7* 37 6 9* 37 6 9* 38 6 10* 30 6 8* 37 6 9* 38 6 11*
*P , 0.003, all t . 3.34 compared with situation with Gp , 2.5 mmol/L.
CTX 5 cortex; STR 5 striatum; HIP 5 hippocampus; THA 5 thalamus; HYP 5 hypothalamus; CB 5 cerebellum; CER 5 cerebrum.
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known. Under hypoglycemia, glucose
transport was lowest in the hypothalamus
as judged from K1,glc1st order and K1,glc.
However, the absolute numbers of the re-
gional analysis must be interpreted with
caution considering the strong scattering
in the data, spillover, and partial-volume
effects.
Decreased 18F-FDG uptake in the hypo-
thalamus was also observed in humans un-
der hypoglycemia (38). Both observations
of high transport at high Gp and low trans-
port at low Gp, with the resulting effects on
Gi as simulated in this study, are of interest
in the context of the suggested mechanism
of glucose sensing in the hypothalamus by
an intracellular glucose-binding sequence
of GLUT2 (9,39). Signaling could be ef-
fective at both extremes of Gp.
We cannot exclude a pharmacologic in-
fluence of insulin on the measured param-
eters. Insulin increases cortical blood flow
in rats at doses of 120 ng/mL in superfused
cerebral spinal fluid (40). We may induce
similar insulin levels in cerebral vessels.
However, our dataset included a hypoglyce-
mic animal without insulin treatment and
a normoglycemic one that received a lower
insulin dose. Both datasets were in agree-
ment with the others. Horinaka et al. (25)
showed that insulin administered under
euglycemia had no effects on CBF, and
previous studies suggested no direct influ-
ence of insulin on KFDG (35). Isoflurane
anesthesia has a significant influence on
cerebral glucose metabolism. Our findings,
therefore, cannot be directly translated to awake mice or mice
under different anesthesia.
CONCLUSION
Glucose plasma-to-brain clearance and phosphorylation rate
constant were increased under hypoglycemia. The alterations, in-
cluding intracellular depletion of glucose, can be quantitatively
described taking into account increased CBF and saturation ki-
netics of GLUT and hexokinase. In contrast to other brain regions,
glucose transport in the hypothalamus did not show significant
saturation and was lower under hypoglycemia but higher at a high
Gp than in other brain regions. This could contribute to the re-
ported glucose-sensing function of the hypothalamus.
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FIGURE 5. Influence of Gp on K1,glc in cortex (A), striatum (B), cerebellum (C), and hypothalamus (D).
Lines as in Figure 2A. Values at Gp of less than 2.0 mmol/L were corrected for expected increase in
CBFby 57%.Hippocampus and thalamus, aswell as Tglc vs.G9p, are presented in Supplemental Figures
12 and 13. R25 0.524 (A), 0.589 (B), 0.399 (C), and 0.289 (D). Solid black line5 fit with Equation 6 (fit
parametersingraph);dashedbluelines595%confidenceband;dashedredlines595%predictionband.
FIGURE 6. Intracellular glucose concentrations of cerebrum (solid line)
and hypothalamus (dashed line) simulated as functions of Gp from fit param-
eters for transport and phosphorylation. Inset shows extended Gp range.
18F-FDG KINETICS IN HYPOGLYCEMIC MOUSE BRAIN • Alf et al. 2159
ACKNOWLEDGMENTS
We thank Alfred Buck, Bruno Weber, and Matthias T. Wyss
(University of Zurich, Switzerland) for fruitful discussions.
REFERENCES
1. Barros LF, Bittner CX, Loaiza A, Porras OH. A quantitative overview of glucose
dynamics in the gliovascular unit. Glia. 2007;55:1222–1237.
2. Kumagai AK, Kang YS, Boado RJ, Pardridge WM. Upregulation of blood-brain
barrier GLUT1 glucose transporter protein and mRNA in experimental chronic hy-
poglycemia. Diabetes. 1995;44:1399–1404.
3. Simpson IA, Appel NM, Hokari M, et al. Blood-brain barrier glucose transporter:
effects of hypo- and hyperglycemia revisited. J Neurochem. 1999;72:238–247.
4. Uehara Y, Nipper V, McCall AL. Chronic insulin hypoglycemia induces GLUT-3
protein in rat brain neurons. Am J Physiol. 1997;272:E716–E719.
5. Lee DH, Chung MY, Lee JU, Kang DG, Paek YW. Changes of glucose trans-
porters in the cerebral adaptation to hypoglycemia. Diabetes Res Clin Pract.
2000;47:15–23.
6. Choi IY, Lee SP, Kim SG, Gruetter R. In vivo measurements of brain glucose
transport using the reversible Michaelis-Menten model and simultaneous
measurements of cerebral blood flow changes during hypoglycemia. J Cereb
Blood Flow Metab. 2001;21:653–663.
7. Pelligrino DA, Segil LJ, Albrecht RF. Brain glucose utilization and transport and
cortical function in chronic vs. acute hypoglycemia. Am J Physiol. 1990;259:
E729–E735.
8. Russo VC, Kobayashi K, Najdovska S, Baker NL, Werther GA. Neuronal pro-
tection from glucose deprivation via modulation of glucose transport and inhi-
bition of apoptosis: a role for the insulin-like growth factor system. Brain Res.
2004;1009:40–53.
9. Stolarczyk E, Guissard C, Michau A, et al. Detection of extracellular glucose by
GLUT2 contributes to hypothalamic control of food intake. Am J Physiol Endo-
crinol Metab. 2010;298:E1078–E1087.
10. Leturque A, Brot-Laroche E, Le Gall M. GLUT2 mutations, translocation, and
receptor function in diet sugar managing. Am J Physiol Endocrinol Metab.
2009;296:E985–E992.
11. Osundiji MA, Hurst P, Moore SP, et al. Recurrent hypoglycemia increases
hypothalamic glucose phosphorylation activity in rats. Metabolism. 2011;60:
550–556.
12. Kuwabara H, Evans AC, Gjedde A. Michaelis-Menten constraints improved
cerebral glucose metabolism and regional lumped constant measurements with
[18F]fluorodeoxyglucose. J Cereb Blood Flow Metab. 1990;10:180–189.
13. Suda S, Shinohara M, Miyaoka M, Lucignani G, Kennedy C, Sokoloff L. The
lumped constant of the deoxyglucose method in hypoglycemia: effects of mod-
erate hypoglycemia on local cerebral glucose utilization in the rat. J Cereb Blood
Flow Metab. 1990;10:499–509.
14. Schuier F, Orzi F, Suda S, Lucignani G, Kennedy C, Sokoloff L. Influence of
plasma glucose concentration on lumped constant of the deoxyglucose method:
effects of hyperglycemia in the rat. J Cereb Blood Flow Metab. 1990;10:765–773.
15. Weber B, Burger C, Biro P, Buck A. A femoral arteriovenous shunt facilitates
arterial whole blood sampling in animals. Eur J Nucl Med Mol Imaging. 2002;
29:319–323.
16. Alf MF, Wyss MT, Buck A, Weber B, Schibli R, Krämer SD. Quantification of
brain glucose metabolism by 18F-FDG PET with real-time arterial and image-
derived input function in mice. J Nucl Med. 2013;54:132–138.
17. Sokoloff L, Reivich M, Kennedy C, et al. The [14C]deoxyglucose method for the
measurement of local cerebral glucose utilization: theory, procedure, and normal
values in the conscious and anesthetized albino rat. J Neurochem. 1977;28:
897–916.
18. Chugh BP, Lerch JP, Yu LX, et al. Measurement of cerebral blood volume in
mouse brain regions using micro-computed tomography. Neuroimage. 2009;47:
1312–1318.
19. Gredell JA, Turnquist PA, Maciver MB, Pearce RA. Determination of diffusion
and partition coefficients of propofol in rat brain tissue: implications for studies
of drug action in vitro. Br J Anaesth. 2004;93:810–817.
20. Hasselbalch SG, Knudsen GM, Holm S, Hageman LP, Capaldo B, Paulson OB.
Transport of D-glucose and 2-fluorodeoxyglucose across the blood-brain barrier
in humans. J Cereb Blood Flow Metab. 1996;16:659–666.
21. Sørensen M, Keiding S. New findings on cerebral ammonia uptake in HE using
functional 13N-ammonia PET. Metab Brain Dis. 2007;22:277–284.
22. Russell ES, Neufeld EF, Higgins CT. Comparison of normal blood picture of young
adults from 18 inbred strains of mice. Proc Soc Exp Biol Med. 1951;78:761–766.
23. Maeda K, Mies G, Olah L, Hossmann KA. Quantitative measurement of
local cerebral blood flow in the anesthetized mouse using intraperitoneal
[14C]iodoantipyrine injection and final arterial heart blood sampling. J Cereb
Blood Flow Metab. 2000;20:10–14.
24. Jay TM, Lucignani G, Crane AM, Jehle J, Sokoloff L. Measurement of local
cerebral blood flow with [14C]iodoantipyrine in the mouse. J Cereb Blood Flow
Metab. 1988;8:121–129.
25. Horinaka N, Artz N, Jehle J, Takahashi S, Kennedy C, Sokoloff L. Examination
of potential mechanisms in the enhancement of cerebral blood flow by hypogly-
cemia and pharmacological doses of deoxyglucose. J Cereb Blood Flow Metab.
1997;17:54–63.
26. Yu AS, Lin HD, Huang SC, Phelps ME, Wu HM. Quantification of cerebral
glucose metabolic rate in mice using 18F-FDG and small-animal PET. J Nucl
Med. 2009;50:966–973.
27. Wong KP, Sha W, Zhang X, Huang SC. Effects of administration route, dietary
condition, and blood glucose level on kinetics and uptake of 18F-FDG in mice.
J Nucl Med. 2011;52:800–807.
28. Backes H, Walberer M, Endepols H, et al. Whiskers area as extracerebral refer-
ence tissue for quantification of rat brain metabolism using 18F-FDG PET: ap-
plication to focal cerebral ischemia. J Nucl Med. 2011;52:1252–1260.
29. Muzi M, Freeman SD, Burrows RC, et al. Kinetic characterization of hexokinase
isoenzymes from glioma cells: implications for FDG imaging of human brain
tumors. Nucl Med Biol. 2001;28:107–116.
30. Duarte JM, Gruetter R. Cerebral glucose transport and homeostasis. In: Choi IY,
Gruetter R, eds. Neural Metabolism In Vivo. New York, NY: Springer; 2012:
655–673.
31. Duarte JM, Gruetter R. Characterization of cerebral glucose dynamics in vivo
with a four-state conformational model of transport at the blood-brain barrier.
J Neurochem. 2012;121:396–406.
32. Gjedde A. High- and low-affinity transport of D-glucose from blood to brain.
J Neurochem. 1981;36:1463–1471.
33. Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localiza-
tion and metabolic function. J Exp Biol. 2003;206:2049–2057.
34. Poitry-Yamate C, Lei H, Gruetter R. The rate-limiting step for glucose transport
into the hypothalamus is across the blood-hypothalamus interface. J Neurochem.
2009;109(suppl 1):38–45.
35. Kreissl MC, Stout DB, Wong KP, et al. Influence of dietary state and insulin on
myocardial, skeletal muscle and brain [F]-fluorodeoxyglucose kinetics in mice.
EJNMMI Res. 2011;1:8.
36. Arluison M, Quignon M, Nguyen P, Thorens B, Leloup C, Penicaud L. Distri-
bution and anatomical localization of the glucose transporter 2 (GLUT2) in the adult
rat brain: an immunohistochemical study. J Chem Neuroanat. 2004;28:117–136.
37. Uldry M, Thorens B. The SLC2 family of facilitated hexose and polyol trans-
porters. Pflugers Arch. 2004;447:480–489.
38. Dunn JT, Cranston I, Marsden PK, Amiel SA, Reed LJ. Attenuation of amygdala
and frontal cortical responses to low blood glucose concentration in asymptom-
atic hypoglycemia in type 1 diabetes: a new player in hypoglycemia unaware-
ness? Diabetes. 2007;56:2766–2773.
39. Thorens B. Brain glucose sensing and neural regulation of insulin and glucagon
secretion. Diabetes Obes Metab. 2011;13(suppl 1):82–88.
40. Katakam PV, Domoki F, Lenti L, et al. Cerebrovascular responses to insulin in
rats. J Cereb Blood Flow Metab. 2009;29:1955–1967.
2160 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 54 • No. 12 • December 2013
